Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare spinal tumor which is highly malignant and tends to be locally invasive of surrounding neural tissue. The tumor also tends to spread throughout the neuroaxis and is often rapidly progressive. Histologically the tumors are highly cellular with nuclear and cellular pleomorphism, endothelial proliferation, mitotic figures, and, often, necrosis. This tumor has a relatively poor prognosis. Clinical features may include pain followed by rapidly progressive neurologic deficits such as extremity weakness, sensory changes, spasticity, and incontinence. (From Innocenzi et al., Clin Neurol Neurosurg 1997 Feb;99(1):1-5)
Biomarker and diagnostic research for adult spinal cord glioblastoma has been reported in the published literature.
No clinical trials have been registered for adult spinal cord glioblastoma.
30 publications have been identified in PubMed for adult spinal cord glioblastoma. Research spans Review / Meta-Analysis (37%), Basic Science / Preclinical (20%), and Case Report / Case Series (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 11 | 37% |
Data assembled from 2 of 12 sources · Last updated Sep 17, 2026, 10:14 PM UTC
Common questions about adult spinal cord glioblastoma
6 |
20% |
Patient case studies | 4 | 13% |
Testing and diagnosis research | 3 | 10% |
Clinical study results | 3 | 10% |
Disease patterns and progression | 2 | 7% |
Other research | 1 | 3% |
Falcó-Roget J (2026). [PMID: 41099361](https://pubmed.ncbi.nlm.nih.gov/41099361/). *Neuro Oncol*. [Diagnostic / Biomarker]
Giorgia I (2026). [PMID: 42143483](https://pubmed.ncbi.nlm.nih.gov/42143483/). *J Clin Neurosci*. [Diagnostic / Biomarker]
Guerra PLN (2026). [PMID: 41261239](https://pubmed.ncbi.nlm.nih.gov/41261239/). *Eur Spine J*. [Review / Meta-Analysis]
Palla A (2026). [PMID: 41734534](https://pubmed.ncbi.nlm.nih.gov/41734534/). *J Clin Neurosci*. [Review / Meta-Analysis]
Kim KW (2025). [PMID: 41032747](https://pubmed.ncbi.nlm.nih.gov/41032747/). *Cancer Res*. [Basic Science / Preclinical]
Konopko M (2025). [PMID: 41693184](https://pubmed.ncbi.nlm.nih.gov/41693184/). *Folia Neuropathol*. [Case Report / Case Series]
Trewin-Nybråten CB (2025). [PMID: 40932639](https://pubmed.ncbi.nlm.nih.gov/40932639/). *J Neurooncol*. [Epidemiology / Natural History]
Eibl T (2025). [PMID: 40924322](https://pubmed.ncbi.nlm.nih.gov/40924322/). *J Neurooncol*. [Clinical Trial Publication]
Muir MT (2025). [PMID: 41099461](https://pubmed.ncbi.nlm.nih.gov/41099461/). *Hum Brain Mapp*. [Clinical Trial Publication]
Endo T (2025). [PMID: 40315614](https://pubmed.ncbi.nlm.nih.gov/40315614/). *J Neurosurg Spine*. [Other]
AI-curated news mentioning adult spinal cord glioblastoma
Updated Mar 6, 2026
New CGCG response assessment criteria for spinal cord gliomas have been proposed, aiming to standardize evaluation methods in clinical settings. This development could enhance treatment strategies and patient outcomes in this rare disease.